白细胞介素2在动脉粥样硬化性心血管疾病抗炎治疗中作用的研究进展  

Research progress in the role of interleukin-2 in anti-inflammatory therapy for atherosclerotic cardiovascular disease

作　　者：孙爽 崔淯夏[1] 陈红[1] 宋俊贤[1] Sun Shuang;Cui Yuxia;Chen Hong;Song Junxian(Department of Cardiology,Peking University People’s Hospital,Center for Cardiovascular Translational Research,Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction,Beijing 100044,China)

机构地区：[1]北京大学人民医院心血管内科,心血管转化医学研究中心,急性心肌梗死早期预警和干预北京市重点实验室,100044

出　　处：《中国心血管杂志》2024年第4期375-378,共4页Chinese Journal of Cardiovascular Medicine

摘　　要：抗炎治疗是降低动脉粥样硬化性心血管疾病(ASCVD)患者心血管残余风险的重要策略。低剂量白细胞介素2通过增加调节性T细胞和Ⅱ型固有淋巴细胞的数量,提高其功能,从而抑制动脉粥样硬化的发生和发展。随着更多研究证实低剂量白细胞介素2在ASCVD抗炎治疗中的有效性和安全性,其有望成为ASCVD抗炎治疗的新选择。Anti-inflammatory therapy is an important strategy to reduce the residual risk of cardiovascular events in patients with atherosclerotic cardiovascular disease.Low dose interleukin-2 inhibits the occurrence and progression of atherosclerosis by increasing both the number and function of regulatory T cells and type 2 innate lymphoid cells.As more studies validate the efficacy and safety of low-dose interleukin-2 in the anti-inflammatory treatment of atherosclerotic cardiovascular disease,it is emerging as a promising new therapeutic option.

关 键 词：动脉粥样硬化性心血管疾病 白细胞介素2 调节性T细胞 Ⅱ型固有淋巴细胞 

分 类 号：R54[医药卫生—心血管疾病]